NASDAQ: ECORElectrocore Inc Stock
$6.07+0.19 (+3.23%)
Updated Jul 20, 2026
ECOR Price
$6.07
Fair Value Price
N/A
Market Cap
$50.35M
52 Week Low
$4.16
52 Week High
$10.50
P/E
-3.43x
P/B
-8.85x
P/S
1.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.90M
Earnings
-$15.38M
Gross Margin
87.2%
Operating Margin
-42.42%
Profit Margin
-44.1%
Debt to Equity
-3.72
Operating Cash Flow
-$7M
Beta
0.85
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ECOR Overview
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ECOR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ECOR
Ranked#67 of 94
Ranked#67 of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.58 | A | |
| $40.88 | A | |
| $30.43 | A |
Be the first to know about important ECOR news, forecast changes, insider trades & much more!
ECOR News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ECOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ECOR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ECOR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ECOR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ECOR due diligence checks available for Premium users.
Valuation
ECOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.43x
Industry
21.57x
Market
11.71x
ECOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.85x
Industry
3.1x
ECOR's financial health
Profit margin
Revenue
$9.6M
Net Income
-$5.3M
Profit Margin
-55%
ECOR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ECOR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$15.5M
Liabilities
$21.2M
Debt to equity
-3.72
ECOR's short-term assets ($12.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ECOR's short-term assets ($12.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ECOR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ECOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
$597.0k
Financing
$230.0k
ECOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ECOR vs Medical Device Stocks
Electrocore Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.